Suppr超能文献

丹麦老年人多药治疗的发生情况和与过早死亡相关的风险:一项基于全国登记的队列研究。

Polypharmacy occurrence and the related risk of premature death among older adults in Denmark: A nationwide register-based cohort study.

机构信息

Methods and Analysis, Statistics Denmark, Copenhagen, Denmark.

Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

出版信息

PLoS One. 2022 Feb 23;17(2):e0264332. doi: 10.1371/journal.pone.0264332. eCollection 2022.

Abstract

BACKGROUND

Polypharmacy, defined as the concurrent use of ≥5 medications, increases the risk of drug-drug and drug-disease interactions as well as non-adherence to drug therapy. This may have negative health consequences particularly among older adults due to age-related pharmacokinetic and pharmacodynamic changes. This study aims to uncover the occurrence of polypharmacy among older adults in Denmark and investigate how polypharmacy relates to mortality.

METHOD

This nationwide register-based study included 1,338,058 adults aged 65+ years between January 2013 and December 2017 in Denmark. Polypharmacy prevalence was measured at time of inclusion while incidence and the association between polypharmacy and mortality were measured over the five-year follow-up using Cox regression. In an attempt to adjust for confounding by indication, propensity scores with overlap weighting were introduced to the regression model.

RESULTS

At time of inclusion, polypharmacy prevalence was 29% and over the five years follow-up, 47% of the remaining adults transitioned into polypharmacy. Identified risk factors included multimorbidity (2+ morbidities: HR = 3.51; 95% CI = 3.48-3.53), age (95+ years: HR = 2.85; 95% CI = 2.74-2.96), socioeconomic factors (Highest income quartile: HR = 0.81; 95% CI = 0.80-0.81), region of birth region (Non-western migrants: HR = 0.77; 95% CI = 0.75-0.79), marital status (Divorced: HR = 1.10; 95% CI = 1.10-1.12) and year of inclusion (2017: HR = 1.19; 95% CI = 1.19-1.22). Further analyses showed that polypharmacy involves many different drug cocktails with medication for the cardiovascular system (95%), blood and blood-forming organs (69%), alimentary tract and metabolism (61%) and nervous system (54%) contributing the most. After adjustment for propensity scores with OW, both polypharmacy (HR = 3.48, CI95% = 3.41-3.54) and excessive polypharmacy (HR = 3.48, CI95% = 3.43-3.53) increased the risk of death substantially.

CONCLUSION

A considerable proportion of older adults in Denmark were exposed to polypharmacy dependent on health status, socio-economic status, and societal factors. The associated three- to four-fold mortality risk indicate a need for further exploration of the appropriateness of polypharmacy among older adults.

摘要

背景

同时使用≥5 种药物的定义为多药治疗,这会增加药物-药物和药物-疾病相互作用以及药物治疗不依从的风险。由于与年龄相关的药代动力学和药效学变化,这可能会对老年人产生负面影响。本研究旨在揭示丹麦老年人中多药治疗的发生情况,并研究多药治疗与死亡率之间的关系。

方法

这项全国范围内的基于登记的研究纳入了 2013 年 1 月至 2017 年 12 月期间 1338058 名 65 岁以上的成年人。在纳入时测量多药治疗的流行率,而在五年随访期间使用 Cox 回归测量多药治疗的发生率和与死亡率之间的关系。为了尝试调整指示性混杂因素,引入了具有重叠加权的倾向评分。

结果

在纳入时,多药治疗的流行率为 29%,在五年的随访期间,其余成年人中有 47%转为多药治疗。确定的风险因素包括合并症(≥2 种疾病:HR=3.51;95%CI=3.48-3.53)、年龄(≥95 岁:HR=2.85;95%CI=2.74-2.96)、社会经济因素(收入最高四分位数:HR=0.81;95%CI=0.80-0.81)、出生地地区(非西方移民:HR=0.77;95%CI=0.75-0.79)、婚姻状况(离婚:HR=1.10;95%CI=1.10-1.12)和纳入年份(2017 年:HR=1.19;95%CI=1.19-1.22)。进一步的分析表明,多药治疗涉及许多不同的药物组合,心血管系统(95%)、血液和造血器官(69%)、消化道和新陈代谢(61%)和神经系统(54%)的药物使用最多。在调整具有 OW 的倾向评分后,多药治疗(HR=3.48,95%CI95%=3.41-3.54)和过度多药治疗(HR=3.48,95%CI95%=3.43-3.53)都显著增加了死亡风险。

结论

丹麦相当一部分老年人暴露于多药治疗中,这取决于健康状况、社会经济地位和社会因素。相关的三到四倍的死亡风险表明需要进一步探讨老年人多药治疗的适宜性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0be9/8865634/fc083b0b8aef/pone.0264332.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验